Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)

NCT04846868 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

620

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Iclepertin
DRUG: Placebo

Sponsor

Boehringer Ingelheim